Tislelizumab Versus Chemotherapy as Second-Line Treatment for Advanced or Metastatic Esophageal Squamous Cell Carcinoma (RATIONALE-302): A Randomized Phase III Study
Lin Shen(Peking University), Ningning Ding(BeiGene (China)), Roberto Pazo-Cid(Hospital Universitario Miguel Servet), Jong‐Mu Sun(Samsung Medical Center), Christophe Borg(Centre Hospitalier Universitaire de Besançon), Sung‐Bae Kim(Ulsan College), Guohua Yu(Qingdao University), Jaffer A. Ajani(The University of Texas MD Anderson Cancer Center), Longzhen Zhang(Xuzhou Medical College), Florian Lordick(Leipzig University), Hiroki Hara(Saitama Cancer Center), Zuoxing Niu(Shandong Tumor Hospital), Taroh Satoh(Osaka University Hospital), Kuaile Zhao(Shanghai Medical College of Fudan University), Qing Bi(Zhejiang Provincial People's Hospital), Jingwen Shi(BeiGene (China)), Yongqian Shu(Jiangsu Province Hospital), Ken Kato(National Cancer Center Hospital East), Eric Van Cutsem(Universitair Ziekenhuis Leuven), Jianhua Chen(Hunan Cancer Hospital), Zhiyong He(Albert Einstein College of Medicine), Zhendong Chen(University of Cologne), Xinmin Yu(Zhejiang Cancer Hospital), Chen‐Yuan Lin(China Medical University), Qi Luo(Nanchang University), Liyun Li(BeiGene (China)), Jufeng Wang(Henan Cancer Hospital), Aiyang Tao(BeiGene (China)), Tienan Yi(Xiangyang Central Hospital), Hendrick-Tobias Arkenau(Sarah Cannon Research Institute)
Cited by 306
Related Papers
Increased Survival in Pancreatic Cancer with nab-Paclitaxel plus Gemcitabine
|New England Journal of Medicine|2013|6.6k
Gastric cancer
|The Lancet|2020|4.8k
Phase 3 Trial of <sup>177</sup> Lu-Dotatate for Midgut Neuroendocrine Tumors
|New England Journal of Medicine|2017|3.2k
Trastuzumab Deruxtecan in Previously Treated HER2-Low Advanced Breast Cancer
|New England Journal of Medicine|2022|2.5k